Inhibitors of tyrosine kinase

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 562-568

  Klohs, Wayne D ^a   Fry, David W ^a   Kraker, Alan J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 AMINOQUINAZOLINE DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CGP 59326; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; PD 166285; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[1,2 A]PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RPR 108518A; SU 0879; SU 149S; SU 1835; SU 4136; UNCLASSIFIED DRUG; VINBLASTINE; WIN 1662;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; META ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030783173     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00012     Document Type: Review

References (39)

1. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR: Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996, 38:67-73.
2. Myers MR, Setzer NN, Spada AP, Persons PE, Ly CQ, Maguire MP, Zulli AL, Cheney DL, Zilberstein A, Johnson SE, Franks CF, Mitchell KJ: The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo [3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity. Bioorg Med Chem Lett 1997, 7:421-424.
3. Gazit A, Chen J, App H, McMahon G, Hirth P, Chen I, Levitzki A: Tyrphostins IV-Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg Med Chem 1996, 4:1203-1207.
4. Han YC, Caday CG, Nanda A, Cavenee WK, Huang HJS. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 1996, 56:3859-3861.
5. Denny WA, Rewcastle GW, Bridges AJ, Fry DW, Kraker AJ: Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin Exp Pharmacol Physiol 1996, 23:424-427.
6. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HDH, Fry DW, Kraker AJ, Denny WA: Tyrosine kinase inhibitors: 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996, 39:267-276.
7. Rewcastle GW, Palmer BD, Bridges AJ, Showalter HDH, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA. Tyrosine kinase inhibitors: 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1996, 39:918-928.
8. Palmer BD, Trumpp-Kallmeyer S, Fry DW, Nelson JM, Showalter HDH, Denny WA: Tyrosine kinase inhibitors: 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding. J Med Chem 1997, 40:1519-1529.
9. Gibson K: Quinazoline derivatives. Newark, DE: Zeneca Limited; Patent WO 96/33980, 1996.
10. Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L, Henthorn LR: ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res 1997, 38:633. Disclosure of Zeneca's epidermal growth factor receptor tyrosine kinase inhibitor currently undergoing clinical trials.
11. Schnur RC, Arnold LD: Quinazoline derivatives. New York, NY: Pfizer Inc.; Patent WO 96/30347, 1996.
12. Iwata K, Miller PE, Barbacci EG, Arnold L, Doty J, DiOrio CI, Pustilnik LR, Reynolds M, Thelemann A, Sloan D, Moyer JD: CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Proc Am Assoc Cancer Res 1997, 38:633. First disclosure of Pfizer's epidermal growth factor receptor tyrosine kinase inhibitor clinical candidate.
13. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Iwata K: Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects. Proc Am Assoc Cancer Res 1997, 38:633.
14. Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou H, Fry DW, McMichael A, Denny WA: Tyrosine kinase inhibitors: 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J Med Chem 1996, 39:1823-1835.
15. Fry DW, Nelson JM, McMichael A, Rewcastle GW, Denny WA, Zhou HR, Bridges AJ: Specific suppression of the epidermal growth factor receptor tyrosine kinase in tumor cells and ensuing inhibition of clone formation in soft agar. Proc Am Assoc Cancer Res 1996, 37:424.
16. Slintak V, Keller PR, Rewcastle GW, Denny WA, Fry DW: PD 158780 is a potent inhibitor of heregulin-dependent tyrosine phosphorylation of erbB2, erbB3, and erbB4. Proc Am Assoc Cancer Res 1997, 38:470.
17. Elliott WL, Fry DW, Vincent PW, Roberts BJ, Howard CT, Slintak V, Nelson JM, Hook KE, Showalter HDH, Winters TR, Denny WA, Thompson AM: In vitro and in vivo activity of 4-anilinopyridopyridimine EGF family specific tyrosine kinase inhibitors. Proc Am Assoc Cancer Res 1997, 38:470. First demonstration of in vivo antitumor activity with a pyridopyrimidine.
18. Denny WA, Palmer BD, Rewcastle GW, Thompson AM, Bridges AJ, Doherty AM, Fry DW, Nelson JM, Rubin JR, Showalter HDH, Trumpp-Kallmeyer S: Pyrido[d]pyrimidine inhibitors of the tyrosine kinase activity of the EGF receptor: A binding model and structure-activity relationships for soluble analogues. Proc Am Assoc Cancer Res 1997, 38:633.
19. Traxler P: Pyrazole derivatives and processes for the preparation thereof. East Hannover, NJ: Ciba-Geigy AG; Patent WO96/31510, 1996.
20. Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N: 4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 1996, 39:2285-2292.
21. Westermark B, Heldin CH: Platelet-derived growth factor: Structure, function and implications in normal and malignant cell growth. Acta Oncol 1993, 32:101-105.
22. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB: Potent and selective inhibitors of the abl-kinase: Phenylaminopyrimidine (PAP) derivatives. Bioorg Med Chem Lett 1997, 7:187-192. Well characterized and highly specific PDGF receptor tyrosine kinase inhibitor.
23. Buchdunger E, Zimmermann J, Mett H, Meyer T, Mueller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
24. Giese NA, Lokker N: Method and compositions for inhibiting protein kinases. World Pat Appl WO 9613259, 9 May, 1996.
25. Giese NA, Lokker N, Laibelman AM, Scarborough RM: Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases. World Pat Appl WO 9614843, 23 May, 1996.
26. Sawutz DG, Bode DC, Briggs M, Reid JR, Canniff P, Caldwell L, Faltynek CR, Miller D, Dunn JA, de Garavilla L, Guiles JW, Weigelt C, Michne W, Treasurywala AM, Silver PJ: In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem Pharmacol 1996, 51:1631-1638.
27. Blankley CJ, Boschelli DH, Doherty AM, Hamby JM, Klutchko S, Panek RL: Pyrido[2,3-d]pyrimidines as protein tyrosine kinase mediated cell proliferation inhibitors. World Pat App WO 9634867, 7 Nov, 1996.
28. Blankley CJ, Doherty AM, Hamby JM, Panek RL, Schroeder MC, Showalter HDH, Connolly C: 6-Aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase-mediated cellular proliferation. World Pat Appl WO 9615128, 23 May, 1996.
29. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA. In vitro pharmacological characterization of PD 166285, a new broadly active protein tyrosine kinase inhibitor. Pharmacol Therapeut, in press. Broad-spectrum receptor tyrosine inhibitor with potent biologic properties.
30. Hamby JM, Connolly CJC, Schroeder MC, Winters RT, Showalter HDH, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, et al.: Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 1997, 40:2296-2303.
31. Klohs W, Steinkampf R, Driscoll D, Klutchko S, Hamby J, Lu G, Vincent P, Roberts B, Elliott W: Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors. Proc Am Assoc Cancer Res 1997, 38:632.
32. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J: Structure of the tyrosine kinase domain of fibroblast factor receptor in complex with inhibitors. Science 1997, 276:955-960.
33. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitski A, Gazit A, et al.: Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56:3540-3545.
34. Bolen JB, Penhallow RC, Burkhardt AL: Signal transduction by the src family of tyrosine protein kinases. In Encyclopedia of Cancer. Edited by Bertino J. San Diego: Academic Press; 1997:1657-1668.
35. c-src in progressive stages of human colorectal cancer. J Clin Invest 1993, 91:53-60.
36. Twamley-Stein GM, Pepperkok R, Ansorge W, Courtneidge SA: The src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cell. Proc Natl Acad Sci U S A 1993, 90:7696-7700.
37. Myers MR, Setzer NN, Spada AP, Zulli AL, Hsu C-YJ, Zilberstein A, Johnson SE, Hook LE, Jacoski MV: The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56 lck and EGF-R tyrosine kinase activity. Bioorg Med Chem Lett 1997, 7:417-420.
38. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA: Discovery of a novel, potent and src-family selective tyrosine kinase inhibitor. J Biol Chem 1996, 271:695-701. Thorough discussion of a novel src tyrosine kinase inhibitor.
39. Kraker AJ, Moore CW, Amar AM, Shen CS, Nelson J, Slintak V, Fry DW, Lu G, Panek R, Klutchko S, Hamby J: Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors of human colon carcinoma cell lines. Proc Amer Assoc Cancer Research 1997, 38:633.